search
Back to results

Influenza Challenge Study of VIS410 in Healthy Volunteers

Primary Purpose

Influenza

Status
Completed
Phase
Phase 2
Locations
Belgium
Study Type
Interventional
Intervention
VIS410
Placebo
Sponsored by
Visterra, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Influenza

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Male or female subjects of age 18-45 years, inclusive, at the time of informed consent.
  2. Women should fulfill one of the following criteria:

    • Post-menopausal; either amenorrhea ≥ 12 months or follicle stimulating hormone > 40 mIU/mL.
    • Surgically sterile; bilateral oophorectomy, hysterectomy, or tubal ligation.
    • Women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception until the end of the study.
    • Must be sexually inactive by abstinence which is consistent with the preferred and usual lifestyle of the subject.
  3. Women of childbearing potential must have a negative pregnancy test at screening (serum) and on Day -2 (urine).
  4. Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects must use an effective birth control method (see Inclusion Criterion 2).
  5. Seronegative for the challenge virus (HAI ≤ 10).

Exclusion Criteria:

  1. Known or suspected intolerance or hypersensitivity to the investigational study drug or virus.
  2. Has an acute or chronic medical condition that would render the investigational study drug unsafe or would interfere with the evaluation of the responses.
  3. Subjects receiving medications that affect the immune system.
  4. Significant adulthood history of seasonal hay fever or a seasonal allergic rhinitis or perennial allergic rhinitis or chronic or nasal or sinus condition.
  5. Subjects who have received any vaccination within the last 3 months or influenza vaccine within the last 6 months.
  6. Subjects with a confirmed diagnosis of influenza A within the last 6 months prior to screening.
  7. Subjects with abnormal nasal structure (including septal deviation and nasal polyps), chronic sinusitis, or reason (i.e., intolerance) that complicates nasopharyngeal swabbing.
  8. Presence of lung disease, asthma, or chronic obstructive pulmonary disease.
  9. Has a history of alcohol or drug abuse.
  10. A positive HIV antibody screen, HBsAg, HBcAb or hepatitis C antibody screen.
  11. Cancer or treatment for cancer, within 3 years, excluding basal cell carcinoma of the skin, which is allowed.
  12. Presence of immunosuppression or any medical condition that may be associated with impaired immune responsiveness.
  13. Anticipated presence of a household contact with potential immunosuppression.
  14. History of Guillain-Barré syndrome.
  15. Current professional activity as a healthcare worker who will return to work within 2 weeks following challenge.
  16. Anticipated presence of a pregnant household contact, within 2 weeks following challenge.
  17. Women who are pregnant or breast-feeding, or consider becoming pregnant.
  18. Acute disease within 2 weeks prior to challenge.
  19. Elevated white blood cell count above 10.90 x 109/L or an absolute neutrophil count above 7.5 x 109/L.
  20. Current enrollment in any other investigational drug study or disease study or participation in an investigational drug study.
  21. Any other reasons for which the investigator considers the subject unfit for the study.

Sites / Locations

  • SGS Life Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

VIS410

Placebo

Arm Description

Single intravenous fixed dose of VIS410

Single intravenous infusion of placebo

Outcomes

Primary Outcome Measures

To assess the effect of VIS410 on the area under the curve of viral shedding over time.
The viral AUC will be measured, qRT-PCR, and compared between treatment groups
To assess the safety profile of VIS410
The proportion of subjects with post-infusion adverse events will be compared between treatment groups.

Secondary Outcome Measures

Assess the effects of VIS410 on viral shedding
The peak viral load and time to cessation of shedding will be measured (qRT-PCR and TCID50)
Assess the pharmacokinetics of VIS410 in serum
The following PK parameters will be calculated: Cmax, tmax, AUC, t1/2, Vd, Cl
Assess the immunogenicity of VIS410
The development of anti-drug antibodies will be measured
Assess the effect of VIS410 on clinical symptoms
The duration of symptoms will be compared between treatment groups
Assess antibody to challenge strain
The HAI antibody titer will be measured

Full Information

First Posted
June 1, 2015
Last Updated
April 4, 2016
Sponsor
Visterra, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02468115
Brief Title
Influenza Challenge Study of VIS410 in Healthy Volunteers
Official Title
A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects After a Viral Inoculation With Influenza A (H1N1)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2016
Overall Recruitment Status
Completed
Study Start Date
May 2015 (undefined)
Primary Completion Date
February 2016 (Actual)
Study Completion Date
February 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Visterra, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A phase 2 a study to assess the safety profile and the effect of VIS410 in healthy subjects after inoculation with influenza A virus (H1N1).
Detailed Description
This is a phase 2a randomized, double-blind, placebo-controlled study to be conducted in healthy volunteers. The study is designed to compare an infusion of a single dose of VIS410 against placebo. Eligible volunteers will be admitted to the clinical center and will receive a single intranasal administration of influenza A (H1N1). One day (24h) after inoculation, subjects will receive a single administration of VIS410 or placebo. Subjects will be confined in the clinical center for 10 days after virus administration. Assessment of safety will be determined from vital sign measurements, physical examinations, hematology, chemistry and urinalysis laboratory testing, 12-lead electrocardiograms (ECGs), pulmonary function, use of concomitant medications, and review of adverse events (AEs) should they occur. During confinement in the clinical center a symptom score card of influenza symptoms will be completed three times a day; nasopharyngeal swabs will be obtained three times a day and assayed for the presence of influenza virus and VIS410 concentration; serum samples will be assayed for VIS410 and the presence of cytokines. Upon release from the clinical center subjects will return for follow-up visits on days 14, 28 and either 56 or 84.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VIS410
Arm Type
Experimental
Arm Description
Single intravenous fixed dose of VIS410
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Single intravenous infusion of placebo
Intervention Type
Drug
Intervention Name(s)
VIS410
Intervention Description
Single fixed IV dose of VIS410
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Single IV dose of placebo
Primary Outcome Measure Information:
Title
To assess the effect of VIS410 on the area under the curve of viral shedding over time.
Description
The viral AUC will be measured, qRT-PCR, and compared between treatment groups
Time Frame
56-84 days
Title
To assess the safety profile of VIS410
Description
The proportion of subjects with post-infusion adverse events will be compared between treatment groups.
Time Frame
56-84 days
Secondary Outcome Measure Information:
Title
Assess the effects of VIS410 on viral shedding
Description
The peak viral load and time to cessation of shedding will be measured (qRT-PCR and TCID50)
Time Frame
10 days
Title
Assess the pharmacokinetics of VIS410 in serum
Description
The following PK parameters will be calculated: Cmax, tmax, AUC, t1/2, Vd, Cl
Time Frame
56-84 days
Title
Assess the immunogenicity of VIS410
Description
The development of anti-drug antibodies will be measured
Time Frame
56-84 days
Title
Assess the effect of VIS410 on clinical symptoms
Description
The duration of symptoms will be compared between treatment groups
Time Frame
10 days
Title
Assess antibody to challenge strain
Description
The HAI antibody titer will be measured
Time Frame
28 days
Other Pre-specified Outcome Measures:
Title
Assess the pharmacokinetics of VIS410 in the nasal mucosa
Description
The following PK parameters will be calculated: Cmax, tmax, AUC, t1/2
Time Frame
10 days
Title
Assess viral target sequence in viral isolates to determine emergence of resistant viruses
Description
Sequencing will be used to determine the emergence of resistant virus in the treatment groups.
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male or female subjects of age 18-45 years, inclusive, at the time of informed consent. Women should fulfill one of the following criteria: Post-menopausal; either amenorrhea ≥ 12 months or follicle stimulating hormone > 40 mIU/mL. Surgically sterile; bilateral oophorectomy, hysterectomy, or tubal ligation. Women of childbearing potential participating in heterosexual sexual relations must be willing to use adequate contraception until the end of the study. Must be sexually inactive by abstinence which is consistent with the preferred and usual lifestyle of the subject. Women of childbearing potential must have a negative pregnancy test at screening (serum) and on Day -2 (urine). Non-vasectomized (or vasectomized less than 6 months prior to dosing) male subjects must use an effective birth control method (see Inclusion Criterion 2). Seronegative for the challenge virus (HAI ≤ 10). Exclusion Criteria: Known or suspected intolerance or hypersensitivity to the investigational study drug or virus. Has an acute or chronic medical condition that would render the investigational study drug unsafe or would interfere with the evaluation of the responses. Subjects receiving medications that affect the immune system. Significant adulthood history of seasonal hay fever or a seasonal allergic rhinitis or perennial allergic rhinitis or chronic or nasal or sinus condition. Subjects who have received any vaccination within the last 3 months or influenza vaccine within the last 6 months. Subjects with a confirmed diagnosis of influenza A within the last 6 months prior to screening. Subjects with abnormal nasal structure (including septal deviation and nasal polyps), chronic sinusitis, or reason (i.e., intolerance) that complicates nasopharyngeal swabbing. Presence of lung disease, asthma, or chronic obstructive pulmonary disease. Has a history of alcohol or drug abuse. A positive HIV antibody screen, HBsAg, HBcAb or hepatitis C antibody screen. Cancer or treatment for cancer, within 3 years, excluding basal cell carcinoma of the skin, which is allowed. Presence of immunosuppression or any medical condition that may be associated with impaired immune responsiveness. Anticipated presence of a household contact with potential immunosuppression. History of Guillain-Barré syndrome. Current professional activity as a healthcare worker who will return to work within 2 weeks following challenge. Anticipated presence of a pregnant household contact, within 2 weeks following challenge. Women who are pregnant or breast-feeding, or consider becoming pregnant. Acute disease within 2 weeks prior to challenge. Elevated white blood cell count above 10.90 x 109/L or an absolute neutrophil count above 7.5 x 109/L. Current enrollment in any other investigational drug study or disease study or participation in an investigational drug study. Any other reasons for which the investigator considers the subject unfit for the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
M Petkova
Organizational Affiliation
SGS Life Sciences, a division of SGS Belgium NV
Official's Role
Principal Investigator
Facility Information:
Facility Name
SGS Life Sciences
City
Antwerp
Country
Belgium

12. IPD Sharing Statement

Citations:
PubMed Identifier
32151645
Citation
Sloan SE, Szretter KJ, Sundaresh B, Narayan KM, Smith PF, Skurnik D, Bedard S, Trevejo JM, Oldach D, Shriver Z. Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge study. Antiviral Res. 2020 Dec;184:104763. doi: 10.1016/j.antiviral.2020.104763. Epub 2020 Mar 7.
Results Reference
derived

Learn more about this trial

Influenza Challenge Study of VIS410 in Healthy Volunteers

We'll reach out to this number within 24 hrs